J-Pharma wins AMED backing of up to ¥1.5bn for biliary cancer trial
J-Pharma's Phase 3 biliary cancer trial was selected for AMED support covering half of eligible costs, up to ¥1.5bn, and the company says full payment would fund Part A without new financing.